Trulicity Guide: Weekly Dulaglutide for Type 2 Diabetes (2026)

Trulicity was the second weekly GLP-1 to hit U.S. pharmacies after Bydureon, and for years it was Eli Lilly's flagship diabetes injectable. It is still widely prescribed in 2026 — especially for patients who want once-weekly dosing and a simple, no-titration auto-injector pen — but the rise of Ozempic and Mounjaro has shifted the conversation.

Direct answer: Trulicity is dulaglutide, a once-weekly subcutaneous GLP-1 receptor agonist from Eli Lilly. The FDA approved it on September 18, 2014 for type 2 diabetes. Doses come pre-filled in single-use pens at 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. At the 1.5 mg dose it lowers A1C by roughly 1.2–1.5 percentage points and produces average weight loss of about 6–10 pounds over 6–12 months. The REWIND cardiovascular outcomes trial in 9,901 patients showed a 12% reduction in major adverse cardiovascular events over a median 5.4 years. List price is approximately $987 per month; commercial savings cards drop costs to as low as $25.

What Trulicity Is

Dulaglutide is a long-acting GLP-1 analogue fused to a modified human IgG4 Fc fragment, which gives it the long half-life needed for weekly dosing. The pen is an auto-injector — the patient does not see the needle and there is no priming or dose dial. Press to skin, click, hold for several seconds.

SkinnyRx

GLP-1 weight loss, prescribed online

Compounded or FDA-approved GLP-1s,
with clinician-guided care.

Complete an online intake and a licensed provider reviews it. FDA-approved options, including Wegovy and Foundayo, are available through the SkinnyRx Membership.

See if you qualify

Semaglutide and tirzepatide · injections or tablets

Prescription required; a licensed provider decides whether treatment is appropriate. Compounded drugs are not FDA-approved or evaluated for safety, effectiveness or quality by the FDA. We may earn a commission.

How Trulicity Works

Trulicity activates the GLP-1 receptor — same biological target as Ozempic (injection and tablets), Wegovy, and Victoza. Once active, the receptor:

• Increases glucose-dependent insulin release from pancreatic beta cells
• Suppresses glucagon secretion when blood sugar is elevated
• Slows gastric emptying
• Reduces appetite via central GLP-1 receptors in the brain
• Improves post-prandial glucose control

The Fc fragment fusion is what makes Trulicity different from short-acting GLP-1s like exenatide twice-daily. It gives dulaglutide a half-life of about 5 days — long enough for once-weekly dosing while staying in a fairly stable plasma concentration window.

How to Take Trulicity

• Inject once weekly on the same day each week, any time of day
• Site rotation: abdomen, thigh, or upper arm
• Injection can be done with or without food
• If a dose is missed and at least 3 days remain until the next scheduled dose, take it as soon as possible; otherwise skip and resume the regular schedule
• If needed, each pen can be kept out of the refrigerator at room temperature (not above 86°F) for a total of up to 14 days
• Store unopened pens refrigerated at 36–46°F

There is no dose dial. Each pen is a fixed strength — moving to a higher dose means switching to a different pen, not adjusting the existing one.

How to give a Trulicity injection with the pen

A Trulicity injection takes three steps: uncap the pen, place it flat on the skin and unlock it, then press and hold the green button until you hear a second click, about 5–10 seconds later (Instructions for Use, Lilly).

Before you start: check the pen strength and expiry date. The liquid should be clear and colorless. Don't use the pen if it is cloudy, discolored or has particles (FDA label).

Choosing a site: inject yourself in the abdomen or thigh. The back of the upper arm works if another person gives the injection. Rotate injection sites every week: the same area is fine, but use a different spot within it (Lilly).

1. Uncap: make sure the pen is locked, pull the gray base cap straight off and throw it away. Don't put it back on and don't touch the needle.
2. Place and unlock: set the clear base flat and firmly on the skin, then turn the lock ring to unlock.
3. Press and hold: press and hold the green injection button. You will hear a loud click. Keep the pen pressed against the skin until a second click (about 5–10 seconds, when the needle retracts), then lift it away. The gray plunger showing in the pen confirms the full dose went in.

Afterwards: a drop of liquid or blood on the skin is normal. Put the used pen in an FDA-cleared sharps container right away, not household trash. Each pen is used once and never shared (FDA label). If you get redness or lumps, see our guide to injection-site reactions.

With insulin: give Trulicity and insulin as separate injections and never mix them. The same body area is fine, but not right next to each other (FDA label).

Changing your injection day: you can move your weekly day if your last dose was at least 3 days earlier. Never take two doses within 3 days of each other (Lilly).

Dosing Schedule

Trulicity uses a straightforward stepwise titration based on glycemic response:

The 3 mg and 4.5 mg doses were added to the label in 2020 after the AWARD-11 trial showed dose-dependent A1C and weight benefit. Most patients land at 1.5 mg as a long-term maintenance dose.

Trulicity dosage chart: adults and children 10+

Every patient starts Trulicity at 0.75 mg once weekly. After 4 weeks the dose can go to 1.5 mg, and adults can then step up in 1.5 mg increments (3 mg, then 4.5 mg), with at least 4 weeks at each dose. The maximum is 4.5 mg for adults and 1.5 mg for children 10 and older (FDA label).

Moving up a step is optional and depends on blood sugar response. Many people stay on a lower dose, and "earliest timing" is not a schedule you must follow (FDA label).

Every strength is a separate single-dose pen holding 0.5 mL. You change the dose by using a different pen, never by splitting or partially injecting one (FDA label).

For children, Trulicity is approved from age 10 with type 2 diabetes. In a 26-week trial of 154 young patients, A1C fell 0.8% on Trulicity and rose 0.6% on placebo (FDA label). No dose change is needed for kidney impairment, including end-stage kidney disease, though the label advises caution in ESRD (FDA label).

For how this compares with other weekly GLP-1s, see our semaglutide dosage chart and tirzepatide dosage chart.

What the REWIND Trial Showed

REWIND is the landmark cardiovascular outcomes trial that distinguishes Trulicity from most older GLP-1s. Published in The Lancet on July 13, 2019, it enrolled 9,901 adults with type 2 diabetes at multiple international sites and ran for a median 5.4 years — the longest follow-up of any GLP-1 cardiovascular outcomes trial.

Key design and result data:

• Mean age: 66.2 years, median A1C 7.2%, 46.3% women
• Only 31.5% had prior cardiovascular disease — making REWIND notable as a primarily primary prevention trial
• Primary endpoint: composite of cardiovascular death, non-fatal MI, non-fatal stroke (3-point MACE)
• Result: 594 events (12.0%) in the dulaglutide group vs. 663 events (13.4%) in placebo — a 12% relative risk reduction, hazard ratio 0.88, statistically significant
• Stroke reduced by ~24% — the strongest single component effect

That primary-prevention profile is unusual among CVOT-positive GLP-1s. SUSTAIN-6 (Ozempic) and LEADER (Victoza) enrolled mostly secondary prevention populations.

A1C and Weight Loss Data

Across the AWARD program (10 Phase 3 trials), Trulicity at the 1.5 mg dose produced:

• A1C reduction: roughly 1.2 to 1.5 percentage points from baseline
• Weight loss: about 6–10 lb over 6–12 months as a secondary outcome
• 3 mg dose: an additional ~0.2 percentage points A1C and ~1–2 lb weight loss vs 1.5 mg
• 4.5 mg dose: ~0.4 additional A1C percentage points and ~3 lb more weight loss vs 1.5 mg

These are diabetes-trial numbers. Trulicity has never been FDA-approved for chronic weight management, and weight effects are smaller than what Ozempic, Wegovy, or Zepbound produce at obesity-trial doses.

Trulicity vs. Ozempic

This is the most-asked comparison in 2026. Both are weekly GLP-1 injections for type 2 diabetes — but they are not equivalent.

SUSTAIN-7, a head-to-head trial of semaglutide 1 mg vs. dulaglutide 1.5 mg over 40 weeks, found semaglutide produced 6.5 kg weight loss vs. 3.0 kg for dulaglutide — more than double. Ozempic generally outperforms Trulicity for both A1C and weight. Trulicity wins on injection simplicity (no dose dial, fully visible pen-stay times), broader primary-prevention CVOT data, and slightly better tolerability for some patients.

Side Effects

Boxed warning: contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Other serious risks include pancreatitis, hypersensitivity reactions, acute kidney injury, severe GI disease (including gastroparesis), gallbladder problems, and diabetic retinopathy complications. Hypoglycemia risk rises when combined with insulin or sulfonylureas.

Cost (2026)

The Lilly savings card caps benefit at $150 per 28-day supply and $1,800 per calendar year, but for most commercially insured patients it brings monthly cost to $25.

Who Trulicity Is Best For

Trulicity tends to be the right choice when:

• Type 2 diabetes is the primary diagnosis, especially with cardiovascular risk factors but no established CVD (the REWIND population)
• The patient strongly prefers an auto-injector with no dose dial and no needle visibility
• Refrigeration constraints make the longer-room-temperature-tolerant Ozempic less practical
• Insurance covers Trulicity better than Ozempic (varies by formulary)
• A1C control is the goal and large weight loss is not the priority

It tends to be a poor fit when:

• Maximum A1C reduction is needed — Ozempic and Mounjaro typically do more
• Significant weight loss is a primary goal — switch to Wegovy, Zepbound, or Mounjaro
• The patient has personal or family history of MTC or MEN 2
• There is severe gastroparesis or recurrent pancreatitis

What People Get Wrong About Trulicity

• "Trulicity is Ozempic." Different molecules. Dulaglutide is a GLP-1-Fc fusion peptide; semaglutide is a modified peptide alone. They share a class, not an exact mechanism profile.
• "Trulicity is approved for weight loss." It is not. Weight effects are a secondary benefit; the indication is type 2 diabetes glycemic control plus cardiovascular risk reduction.
• "The 4.5 mg pen is the standard maintenance dose." Most patients sit at 1.5 mg long-term. Higher doses are titration options when A1C remains above target.
• "Trulicity can be reused like an insulin pen." Each pen is single-use. There is no dose dial — the entire pen empties in one injection.
• "You have to inject in the morning." Trulicity can be injected any time of day, with or without food. Only the weekly schedule matters.
• "REWIND proved Trulicity prevents heart attacks in healthy adults." REWIND showed a 12% MACE reduction in patients with type 2 diabetes and cardiovascular risk factors — not in people without diabetes.

Frequently Asked Questions

How long has Trulicity been on the market? The FDA approved Trulicity on September 18, 2014, so it has roughly a decade of post-marketing data in 2026.

Is Trulicity better than Ozempic? For pure A1C and weight outcomes, Ozempic generally edges out Trulicity in head-to-head data (SUSTAIN-7). Trulicity has stronger primary-prevention cardiovascular data via REWIND and is often easier to inject because the pen has no dose dial.

Can Trulicity cause weight loss? Yes — typically 6–10 lb at the 1.5 mg dose, slightly more at 3 mg and 4.5 mg. It is not approved for chronic weight management, but weight effects are real.

What is the maximum dose of Trulicity? 4.5 mg once weekly, added to the label in 2020 after the AWARD-11 trial.

Does Trulicity need to be refrigerated? Unopened pens stay refrigerated at 36–46°F. Once removed from the fridge, a pen can be kept at room temperature (not above 86°F) for a total of up to 14 days — shorter than Ozempic's 56-day room-temperature window.

Is there a generic Trulicity? Not in the U.S. as of May 2026. Dulaglutide patent protection runs into the late 2020s, so generic versions are not yet available.

Can I miss a dose of Trulicity? If at least 3 days remain until the next scheduled dose, take the missed dose as soon as possible. If less than 3 days remain, skip it and resume the regular schedule.

How do you increase your Trulicity dose? Start at 0.75 mg weekly for 4 weeks, then 1.5 mg if more blood sugar control is needed. Adults can step up to 3 mg and then 4.5 mg, staying at least 4 weeks on each dose (FDA label).

What is the Trulicity dose for children? Trulicity is approved for children 10 and older with type 2 diabetes. They start at 0.75 mg weekly and can increase to a maximum of 1.5 mg after at least 4 weeks (FDA label).

Where do you inject Trulicity? Under the skin of the abdomen or thigh. The back of the upper arm can be used if someone else gives the injection. Rotate to a new spot each week (Lilly).

How long do you hold the Trulicity pen against your skin? Until you hear the second click, about 5–10 seconds after pressing the green button. The gray plunger becomes visible when the dose is complete (FDA label).

Can I change the day I take Trulicity? Yes, as long as your last dose was at least 3 days (72 hours) before the new day. Don't take two doses within 3 days of each other (Lilly).

Last reviewed: May 13, 2026

Sources

• TRULICITY Prescribing Information (FDA Label, 2024)
• Trulicity for Cardiovascular Disease — REWIND Trial (Lilly)
• Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND) — The Lancet
• FDA Approves Trulicity (Lilly Press Release, 2014)
• Trulicity (dulaglutide) FDA Approval History — Drugs.com
• Trulicity 2026 Prices, Coupons & Savings — GoodRx
• Trulicity Costs in 2026: With and Without Insurance — Noom
• TRULICITY Prescribing Information and Instructions for Use (DailyMed, revised March 2026)
• How to Take Trulicity (Lilly)